vs
Aligos Therapeutics, Inc.（ALGS）与NEUROCRINE BIOSCIENCES INC（NBIX）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是Aligos Therapeutics, Inc.的4766.3倍（$805.5M vs $169.0K）。NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -11763.9%，领先11783.0%）。NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs -72.1%）。过去两年NEUROCRINE BIOSCIENCES INC的营收复合增速更高（25.0% vs -50.7%）
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
ALGS vs NBIX — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $169.0K | $805.5M |
| 净利润 | $-19.9M | $153.7M |
| 毛利率 | — | 97.8% |
| 营业利润率 | -12907.7% | 26.2% |
| 净利率 | -11763.9% | 19.1% |
| 营收同比 | -72.1% | 28.3% |
| 净利润同比 | 75.8% | 49.1% |
| 每股收益（稀释后） | $4.23 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $169.0K | $805.5M | ||
| Q3 25 | $741.0K | $794.9M | ||
| Q2 25 | $965.0K | $687.5M | ||
| Q1 25 | $311.0K | $572.6M | ||
| Q4 24 | $606.0K | $627.7M | ||
| Q3 24 | $1.3M | $622.1M | ||
| Q2 24 | $1.1M | $590.2M | ||
| Q1 24 | $694.0K | $515.3M |
| Q4 25 | $-19.9M | $153.7M | ||
| Q3 25 | $-31.5M | $209.5M | ||
| Q2 25 | $-15.9M | $107.5M | ||
| Q1 25 | $43.1M | $7.9M | ||
| Q4 24 | $-82.2M | $103.1M | ||
| Q3 24 | $-19.3M | $129.8M | ||
| Q2 24 | $5.1M | $65.0M | ||
| Q1 24 | $-34.9M | $43.4M |
| Q4 25 | — | 97.8% | ||
| Q3 25 | — | 98.2% | ||
| Q2 25 | — | 98.4% | ||
| Q1 25 | — | 98.4% | ||
| Q4 24 | — | 98.5% | ||
| Q3 24 | — | 98.7% | ||
| Q2 24 | — | 98.4% | ||
| Q1 24 | — | 98.5% |
| Q4 25 | -12907.7% | 26.2% | ||
| Q3 25 | -3827.4% | 30.1% | ||
| Q2 25 | -1924.0% | 21.2% | ||
| Q1 25 | -6187.5% | 4.1% | ||
| Q4 24 | -3393.2% | 22.6% | ||
| Q3 24 | -1610.5% | 29.5% | ||
| Q2 24 | -2489.5% | 24.6% | ||
| Q1 24 | -3176.7% | 19.3% |
| Q4 25 | -11763.9% | 19.1% | ||
| Q3 25 | -4256.0% | 26.4% | ||
| Q2 25 | -1643.8% | 15.6% | ||
| Q1 25 | 13854.7% | 1.4% | ||
| Q4 24 | -13556.1% | 16.4% | ||
| Q3 24 | -1540.7% | 20.9% | ||
| Q2 24 | 477.0% | 11.0% | ||
| Q1 24 | -5023.5% | 8.4% |
| Q4 25 | $4.23 | $1.49 | ||
| Q3 25 | $-3.04 | $2.04 | ||
| Q2 25 | $-1.53 | $1.06 | ||
| Q1 25 | $-2.11 | $0.08 | ||
| Q4 24 | $-13.10 | $1.00 | ||
| Q3 24 | $-3.07 | $1.24 | ||
| Q2 24 | $0.81 | $0.63 | ||
| Q1 24 | $-5.58 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.8M | $713.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $53.5M | $3.3B |
| 总资产 | $88.5M | $4.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $77.8M | $713.0M | ||
| Q3 25 | $99.1M | $340.2M | ||
| Q2 25 | $122.9M | $264.0M | ||
| Q1 25 | $137.9M | $194.1M | ||
| Q4 24 | $56.9M | $233.0M | ||
| Q3 24 | $74.9M | $349.1M | ||
| Q2 24 | $94.5M | $139.7M | ||
| Q1 24 | $112.7M | $396.3M |
| Q4 25 | $53.5M | $3.3B | ||
| Q3 25 | $71.8M | $3.0B | ||
| Q2 25 | $101.9M | $2.7B | ||
| Q1 25 | $116.4M | $2.5B | ||
| Q4 24 | $-29.0M | $2.6B | ||
| Q3 24 | $50.1M | $2.7B | ||
| Q2 24 | $67.2M | $2.5B | ||
| Q1 24 | $59.8M | $2.4B |
| Q4 25 | $88.5M | $4.6B | ||
| Q3 25 | $109.8M | $4.3B | ||
| Q2 25 | $134.7M | $3.9B | ||
| Q1 25 | $150.7M | $3.7B | ||
| Q4 24 | $70.1M | $3.7B | ||
| Q3 24 | $88.4M | $3.5B | ||
| Q2 24 | $108.8M | $3.3B | ||
| Q1 24 | $127.9M | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-21.7M | $388.4M |
| 自由现金流经营现金流 - 资本支出 | — | $386.0M |
| 自由现金流率自由现金流/营收 | — | 47.9% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | 2.53× |
| 过去12个月自由现金流最近4个季度 | — | $743.9M |
8季度趋势，按日历期对齐
| Q4 25 | $-21.7M | $388.4M | ||
| Q3 25 | $-24.3M | $227.5M | ||
| Q2 25 | $-15.5M | $102.0M | ||
| Q1 25 | $-20.9M | $64.8M | ||
| Q4 24 | $-18.4M | $242.5M | ||
| Q3 24 | $-20.1M | $158.0M | ||
| Q2 24 | $-19.5M | $64.6M | ||
| Q1 24 | $-22.7M | $130.3M |
| Q4 25 | — | $386.0M | ||
| Q3 25 | — | $214.3M | ||
| Q2 25 | — | $89.5M | ||
| Q1 25 | — | $54.1M | ||
| Q4 24 | — | $235.2M | ||
| Q3 24 | — | $149.9M | ||
| Q2 24 | — | $53.0M | ||
| Q1 24 | — | $119.1M |
| Q4 25 | — | 47.9% | ||
| Q3 25 | — | 27.0% | ||
| Q2 25 | — | 13.0% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 37.5% | ||
| Q3 24 | — | 24.1% | ||
| Q2 24 | — | 9.0% | ||
| Q1 24 | — | 23.1% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 2.2% |
| Q4 25 | — | 2.53× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | -0.49× | 8.20× | ||
| Q4 24 | — | 2.35× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | -3.85× | 0.99× | ||
| Q1 24 | — | 3.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALGS
暂无分部数据
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
